The content on this site is intended for healthcare professionals only
Dr Constantia Pantelidou speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about a study which looked at the immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer (TNBC).
She reports that PARP inhibitors induce an anti-tumour immune response in BRCA1-deficient TNBC but not in BRCA1-proficient TNBC.
Dr Pantelidou explains that this T cell recruitment is mediated through activation of the STING pathway and this activation is sufficient for the anti-tumour immune response to PARP inhibitors.
ASCO 2026: Breast cancer overview
Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
OncoAlert Round Up for August 25th - 31st, 2023
